Literature DB >> 28714726

Pilot investigation of a phosphatidylethanol-based contingency management intervention targeting alcohol use.

Michael G McDonell1, Jordan Skalisky1, Emily Leickly1, Michael F Orr2, Sterling McPherson3, John Roll3, Nathalie Hill-Kapturczak4, Martin Javors4.   

Abstract

Phosphatidylethanol (PEth) can be detected in blood from 14 to as many as 28 days after alcohol consumption, depending on the amount and frequency of alcohol consumed. PEth may have utility for verifying abstinence in a contingency management (CM) intervention for alcohol use, particularly in settings where frequent verification of abstinence is impossible or impractical. Five nontreatment-seeking heavy drinkers (40% men) participated in an 11-week, ABA-phased within-subject experiment for which they submitted blood spots for PEth measurement, urine samples for ethyl glucuronide (EtG) testing, and self-report drinking data weekly. Participants received reinforcers for submitting samples throughout the A phases. During the B phase (CM phase), they received additional reinforcers when their PEth level was reduced from the previous week and was verified by a negative EtG (<150 ng/ml) urine test and self-report. PEth, EtG, and self-report outcomes were compared between A phases (Weeks 1-3, 8-11) and B phases (Weeks 4-7). During the A phases, 23% of PEth results indicated alcohol abstinence, whereas 53% of PEth samples submitted during the CM (B phase) indicated alcohol abstinence. Participants were more likely to submit EtG-negative urine samples and report lower levels of drinking and heavy drinking during the B phase, relative to the A phases. We also explored the ability of PEth to detect self-reported drinking. The combined PEth homologs (16:0/18:1 and 16:0/18:2) predicted self-reported drinking with area under the curve from 0.81 (1 week) to 0.80 (3 weeks). Results support the initial feasibility of a Peth-based CM intervention. (PsycINFO Database Record (c) 2017 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28714726      PMCID: PMC6004316          DOI: 10.1037/adb0000293

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  22 in total

Review 1.  Actual causes of death in the United States, 2000.

Authors:  Ali H Mokdad; James S Marks; Donna F Stroup; Julie L Gerberding
Journal:  JAMA       Date:  2004-03-10       Impact factor: 56.272

2.  Prize-based contingency management for the treatment of substance abusers: a meta-analysis.

Authors:  Lois A Benishek; Karen L Dugosh; Kim C Kirby; Jason Matejkowski; Nicolle T Clements; Brittany L Seymour; David S Festinger
Journal:  Addiction       Date:  2014-05-23       Impact factor: 6.526

3.  Stability of Phosphatidylethanol in Dry Blood Spot Cards.

Authors:  Ludmila N Bakhireva; Shikhar Shrestha; Hilda L Gutierrez; Mike Berry; Cheryl Schmitt; Dusadee Sarangarm
Journal:  Alcohol Alcohol       Date:  2015-10-29       Impact factor: 2.826

4.  Using ethyl glucuronide in urine to detect light and heavy drinking in alcohol dependent outpatients.

Authors:  Michael G McDonell; Jordan Skalisky; Emily Leickly; Sterling McPherson; Samuel Battalio; Jenny R Nepom; Debra Srebnik; John Roll; Richard K Ries
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

5.  A randomized study of cellphone technology to reinforce alcohol abstinence in the natural environment.

Authors:  Sheila M Alessi; Nancy M Petry
Journal:  Addiction       Date:  2013-01-30       Impact factor: 6.526

6.  A Randomized Controlled Trial of Ethyl Glucuronide-Based Contingency Management for Outpatients With Co-Occurring Alcohol Use Disorders and Serious Mental Illness.

Authors:  Michael G McDonell; Emily Leickly; Sterling McPherson; Jordan Skalisky; Debra Srebnik; Frank Angelo; Roger Vilardaga; Jenny R Nepom; John M Roll; Richard K Ries
Journal:  Am J Psychiatry       Date:  2017-01-31       Impact factor: 18.112

7.  Low plasma antibodies specific for phosphatidylethanol in alcohol abusers and patients with alcoholic pancreatitis.

Authors:  Antti E Nissinen; L Maria Laitinen; Sakari Kakko; Anders Helander; Markku J Savolainen; Sohvi Hörkkö
Journal:  Addict Biol       Date:  2011-02-11       Impact factor: 4.280

Review 8.  Phosphatidylethanol in blood (B-PEth): a marker for alcohol use and abuse.

Authors:  Anders Isaksson; Lisa Walther; Therese Hansson; Anders Andersson; Christer Alling
Journal:  Drug Test Anal       Date:  2011-03-25       Impact factor: 3.345

9.  Phosphatidylethanol: normalization during detoxification, gender aspects and correlation with other biomarkers and self-reports.

Authors:  Friedrich Martin Wurst; Natasha Thon; Steina Aradottir; Susanne Hartmann; Gerhard Adam Wiesbeck; Otto Lesch; Katrin Skala; Manfred Wolfersdorf; Wolfgang Weinmann; Christer Alling
Journal:  Addict Biol       Date:  2010-01       Impact factor: 4.280

Review 10.  Implementing Effective Substance Abuse Treatments in General Medical Settings: Mapping the Research Terrain.

Authors:  Lori J Ducharme; Redonna K Chandler; Alex H S Harris
Journal:  J Subst Abuse Treat       Date:  2015-07-08
View more
  3 in total

1.  Pilot Study of an Integrated Smartphone and Breathalyzer Contingency Management Intervention for Alcohol Use.

Authors:  Oladunni Oluwoye; Hailey Reneau; Jalene Herron; Karl C Alcover; Sterling McPherson; John Roll; Michael G McDonell
Journal:  J Addict Med       Date:  2020 May/Jun       Impact factor: 4.647

2.  Mixed-methods trial of a phosphatidylethanol-based contingency management intervention to initiate and maintain alcohol abstinence in formerly homeless adults with alcohol use disorders.

Authors:  Elizabeth R Fraser; Nathalie Hill-Kapturczak; Julianne Jett; Rachael Beck; Oladunni Oluwoye; Liat S Kriegel; Karl C Alcover; Sterling McPherson; Leopoldo J Cabassa; Martin Javors; Michael G McDonell
Journal:  Contemp Clin Trials Commun       Date:  2021-03-08

3.  Crossover associations of alcohol and smoking, craving and biochemically verified alcohol and nicotine use in heavy drinking smokers.

Authors:  Crystal Lederhos Smith; Garrett Jenkins; Ekaterina Burduli; Phoebe Tham; Andre Miguel; John Roll; Sterling Mcpherson
Journal:  Behav Pharmacol       Date:  2020-10       Impact factor: 2.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.